Clinical decision support eliminated 42% of duplicate orders for medication

A computerized physician order entry (CPOE) system with a clinical decision support (CDS) system could reduce duplicate medications and adverse drug reactions, according to a study published in JMIR Medical Informatics.

In this study, researchers from Taipei Medical University in Taiwan outlined the development of PharmaCloud, a national mediation repository and online query system, and its impact on reducing medication duplication and adverse drug reactions. The system allows physicians to gain access to the medication records of patients, even from different healthcare organizations from across Taiwan.

Researchers began by developing the CDS to download patients' medication history from the PharmaCloud to detect duplicate medications and if a duplicate is detected, the physician receives an alert. Data on time, prescribes drugs and physician responses were collected for three months.

A total of 178,000 prescriptions were prescribed and 43,844 received content from patients allowing physicians access to their medication history though PharmaCloud. Results showed the rate of medication duplication was 5.83 percent, but 42 percent of those potential duplications were flagged and eventually canceled.

“The CDS engine could easily extend functions for detection of adverse drug reactions when more and more electronic health record systems are adopted. Moreover, the CDS engine can retrieve more updated and completed medication histories in the PharmaCloud, so it can have better performance for detection of duplicate medications,” wrote first author Cheng-Yi Yang, PhD, and colleagues. “The successful key component of a CDS engine is the completeness of the patient’s medication history, thus further research to assess the factors in increasing the PharmaCloud consent rate is required.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.